HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD. Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Stock
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.46 CNY | -5.12% |
|
-2.03% | +3.63% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.36B 189M | Sales 2025 * | 1.75B 243M | Capitalization | 7.3B 1.01B |
|---|---|---|---|---|---|
| Net income 2024 * | 378M 52.32M | Net income 2025 * | 513M 71.01M | EV / Sales 2024 * | 5.35 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.16 x |
| P/E ratio 2024 * |
19.5
x | P/E ratio 2025 * |
14.3
x | Employees | 1,321 |
| Yield 2024 * |
1.68% | Yield 2025 * |
1.8% | Free-Float | 50.47% |
More Fundamentals
* Assessed data
More news
| 1 day | -5.12% | ||
| 1 week | -2.03% | ||
| Current month | -2.03% | ||
| 1 month | -9.10% | ||
| 3 months | +2.20% | ||
| 6 months | -1.50% | ||
| Current year | +3.63% |
1 week
67.40
73.52
1 month
65.3076.17
Current year
51.0177.78
1 year
51.0177.78
3 years
51.01120.00
5 years
51.01120.00
10 years
51.01120.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jin Fang Lou
CEO | Chief Executive Officer | 56 | 15-07-31 |
Dong Bo Yan
DFI | Director of Finance/CFO | 33 | 23-01-31 |
| 43 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hui Lin Li
BRD | Director/Board Member | 67 | 19-06-25 |
Yong Zhou Hu
BRD | Director/Board Member | 74 | 19-06-25 |
Jin Fang Lou
CEO | Chief Executive Officer | 56 | 15-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 67.46 | -5.12% | 2,460,488 |
| 24-05-09 | 71.1 | -1.04% | 1,058,800 |
| 24-05-08 | 71.85 | -1.83% | 946,100 |
| 24-05-07 | 73.19 | +1.65% | 1,162,674 |
End-of-day quote Shenzhen S.E., May 09, 2024
More quotes
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a China-based company mainly engaged in comprehensive pharmaceutical technology research and development (R&D). The services provided by the Company mainly include entrusted R&D of pharmaceutical technology and transformation of independent R&D technological achievements. The entrusted R&D business provides integrated pharmaceutical R&D services such as pharmaceutical research, clinical trial and registration application for major pharmaceutical enterprises and pharmaceutical R&D investment enterprises. The transformation business of independent R&D technological achievements is based on the independent project research and development of drug R&D platform, and actively promote the transformation of independent R&D technological achievements after obtaining phased R&D achievements.
Calendar
2024-05-16
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
67.46
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.63% | 1.01B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- 301096 Stock